Cell Reports · 2024 · 35 citations · 39 references
Life SciencesBiotechnologyImmunologyCell TherapyInnate ImmunityStem Cell BiologyChimeric Antigen Receptor T-cell TherapyImmune Cell EngineeringStem Cell BioengineeringTissue Engineering With Stem CellsChimeric Antigen Receptor DesignEpidermal Growth Factor Receptor SignalingImmune RejectionImmune Rejection MechanismsInnate Immune ProtectionRegulatory T Cell EngineeringStem Cell-derived Beta CellsStem Cell-derived Immune Cells
Regenerative medicine is a rapidly expanding field harnessing human pluripotent stem cell (hPSC)-derived cells and tissues to treat many diseases, including type 1 diabetes. However, graft immune protection remains a key challenge. Chimeric antigen receptor (CAR) technology confers new specificities to effector T cells and immunosuppressive regulatory T cells (Tregs). One challenge in CAR design is identifying target molecules unique to the cells of interest. Here, we employ combinatorial genetic engineering to confer CAR-Treg-mediated localized immune protection to stem cell-derived cells. We engineered hPSCs to express truncated epidermal growth factor receptor (EGFRt), a biologically inert and generalizable target for CAR-Treg homing and activation, and generated CAR-Tregs recognizing EGFRt. Strikingly, CAR-Tregs suppressed innate and adaptive immune responses in vitro and prevented EGFRt-hPSC-derived pancreatic beta-like cell (sBC [stem cell-derived beta cell]) graft immune destruction in vivo. Collectively, we provide proof of concept that hPSCs and Tregs can be co-engineered to protect hPSC-derived cells from immune rejection upon transplantation.
39
IL-10 inhibits cytokine production by activated macrophages
David Fiorentino, Albert Zlotnik, Tim R. Mosmann et al. · The Journal of Immunology · 1991 · 2.9K citations · Full text
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch et al. · Science Translational Medicine · 2015 · 1K citations